Copaxone in therapy of remittent disseminated sclerosis patients
Twenty three remittent disseminated sclerosis patients have been observed for two years to study the influence of copaxone on clinical manifestations and course of their disease in relation to the state of membrane- destabilizing processes in erythrocytes.
Main Authors: | O. A. Kitcherova, L. I. Reikhert, S. M. Bychenko, A. A. Sokolova |
---|---|
Format: | Article |
Language: | English |
Published: |
Siberian State Medical University (Tomsk)
2008-09-01
|
Series: | Бюллетень сибирской медицины |
Subjects: | |
Online Access: | https://bulletin.ssmu.ru/jour/article/view/3503 |
Similar Items
-
The basis of membrane stabilized effect of kopaxon in multiple sclerosis
by: L. I. Reikhert, et al.
Published: (2009-02-01) -
RESULTS OF AN OPEN-LABEL COMPARATIVE RANDOMIZED CLINICAL TRIAL OF AXOGLATIRAN® FS (F-SINTEZ, RUSSIA) EFFICIENCY AND SAFETY IN COMPARISON WITH COPAXONE®-TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: F. A. Khabirov, et al.
Published: (2017-01-01) -
Effectiveness of Copaxone in patients with relapsing-remitting multiple sclerosis
by: V. M. Alifirova, et al.
Published: (2010-08-01) -
INFLUENCE OF ENALAPRIL, DIGOXIN, ATENOLOL AND DILTIAZEM ON LIPID PEROXIDATION IN EXPERIMENTAL MODEL OF COMPLEX METABOLIC DISORDERS
by: A. A. Usanova, et al.
Published: (2016-01-01) -
Comparative assessment of hepatoprotective effects of various liposome formulations in experimental venous congestion-induced chronic liver insufficiency
by: R. A. Mukhamadiyarov, et al.
Published: (2012-08-01)